1. Available at http://www.cdc.gov/media/releases/2011/p0126_diabetes.html. Accessed November 3, 2011.
2. Bjornholt JV, Erikssen G, Aaser E, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care. 1999 Jan;22(1):45-9.
3. Bardini G, Dicembrini I, Cresci B, Rotella CM. Inflammation markers and metabolic characteristics of subjects with one-hour plasma glucose levels. Diabetes Care. 2010 Feb;33(2):411-3.
4. Stattin P, Bjor O, Ferrari P, Lukanova A, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007 Mar;30(3):561-7.
5. Batty GD, Kivimäki M, Smith GD, Marmot MG, Shipley MJ. Post-challenge blood glucose concentration and stroke mortality rates in non-diabetic men in London: 38-year follow-up of the original Whitehall prospective cohort study. Diabetologia. 2008 Jul;51:1123-6.
6. Singleton JR, Smith AG, Bromberg, MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24(8)1448-53.
7. Beckley ET. ADA Scientific Sessions: Retinopathy Found in Pre-Diabetes. DOC News. 2005 Aug;2(8):1-10.
8. Polhill TS, Saad S, Poronnik SSP, Fulcher GR, Pollock CA. Short-term peaks in glucose promote renal fibrogenesis independently of total glucose exposure. Am J Physiol Renal Physiol. 2004 Aug;287(2):F268-73.
9. Pan WH, Cedres LB, Liu K, et al. Relationships of clinical diabetes and symptomatic hyperglycaemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol. 1986 Mar;123(3):504-16.
10. Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA.1991 Feb 6;265(5):627-31.
11. Coutinho M, Gerstein H, Poque J, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999 Feb;22(2):233-40.
12. Wilson PWF, Cupples LA, Kannel WB. Is hyperglycaemia associated with cardiovascular disease? The Framingham Study. Am Heart J. 1991 Feb;121 (2 Pt 1):586-90.
13. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn study. Diabetologia. 1999 Aug;42(8):926-31.
14. DECODE Study Group 2001, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of the fasting and the 2-hour diagnostic criteria. Arch Intern Med. 2001 Feb 12;161(3):397-404.
15. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Post-challenge hyperglycemia and mortality in a national sample of US adults. Diabetes Care. 2001 Aug;24(8):1397-402.
16. Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology. 2010 Aug 31;75(9):764-70.
17. Nagendran MV. Effect of Green Coffee Bean Extract (GCE), High in Chlorogenic Acids, on Glucose Metabolism. Poster presentation number: 45-LB-P. Obesity 2011, the 29th Annual Scientific Meeting of the Obesity Society. Orlando, Florida. October 1-5, 2011.
18. Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med. 2008 Jun;121(6):519-24.
19. Kato M, Noda M, Suga H, Matsumoto M, Kanazawa Y. Fasting plasma glucose and incidence of diabetes—implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA cohort study. J Atheroscler Thromb. 2009;16(6):857-61.
20. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist. 2010 May 17;15:548-55.
21. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Cancer Prev Res (Phila). 2011 Jun 22.
22. Czyzyk A, Szczepanik Z. Diabetes mellitus and cancer. Eur J Intern Med. 2000 Oct;11(5):245-52.
23. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009 Dec;16(4):1103-23.
24. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2010 Mar 21;9(6):1057-64.
25. Cust AE, Kaaks R, Friedenreich C, Bonnet F, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition EPIC. Endocr Relat Cancer. 2007 Sep;14(3):755-67.
26. Rosato V, Tavani A, Bosetti C, et al. Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis. Metabolism. 2011 May 5.
27. Stocks T, Lukanova A, Bjørge T, et al. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can): Metabolic Syndrome Cancer Project (Me-Can) Group. Cancer. 2010 Dec 17.
28. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999 Jul 7;91(13):1147-54.
29. Healy L, Howard J, Ryan A, et al. Metabolic syndrome and leptin are associated with adverse pathological features in male colorectal cancer patients. Colorectal Dis. 2011 Jan 20.
30. Held C, Gerstein HC, Zhao F, et al. Fasting plasma glucose is an independent predictor of hospitalization for congestive heart failure in high-risk patients. American Heart Association 2006 Scientific Sessions. November 13, 2006. Abstract 2562.
31. Lamblin N, Bauters C. Hemoglobin A1c levels are associated with severity and prognosis of systolic chronic heart failure in nondiabetic patients. American Heart Association 2006 Scientific Sessions. November 13, 2006. Abstract 2372.
32. Cukierman-Yaffe T, Gerstein HC, Williamson JD. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care. 2009 Mar;32(2):221-6.
33. Sonnen JA, Larson EB, Brickell K. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol.2009;66(3):315-22.
34. Bash, LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident kidney disease even in the absence of albuminuria and retinopathy: atherosclerosis risk in communities (ARIC) study. Arch Intern Med. 2008 Dec 8;168(22):2440-7.
35. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, De Fronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004 Jan;47(1):31-9.
36. Cheng YJ, Gregg EW, Geiss LS. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the US population: implications for diabetes diagnostic thresholds. Diabetes Care. 2009 Nov;32(11):2027-32.
37. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003 Jan 14;60(1):108-11.
38. Hoffman-Snyder C, Smith BE, Ross MA, Hernandez J, Bosch EP. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol. 2006 Aug;63(8):1075-9.
39. Li Q, Chen AH, Song XD, et al. Analysis of glucose levels and the risk for coronary heart disease in elderly patients in Guangzhou Haizhu district. Nan Fang Yi Ke Da Xue Xue Bao. 2010 Jun;30(6):1275-8.
40. Matthews CE, Sui X, LaMonte MJ, Adams SA, Heebert JR, Blair SN. Metabolic syndrome and risk of death from cancers of the digestive system. Metabolism. 2010 Aug;59(8):1231-9.
41. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999 Aug 21;354(9179):617-21.
42. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004 Mar;47(3):385-94.
43. Miura K, Kitahara Y, Yamagishi S. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats. Horm Metab Res. 2010 Sep;42(10):731-5.
44. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care. 2008 Feb;31 Suppl 2:S150-4.
45. Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol. 2008 Nov;2(6):1094-100.
46. Triggle CR. The early effects of elevated glucose on endothelial function as a target in the treatment of type 2 diabetes. Timely Top Med Cardiovasc Dis. 2008;12:E3.
47. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. J Am Coll Cardiol. 1999 Mar;33(3):612-9.
48. Lin HJ, Lee BC, Ho YL, et al. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. Diabetes Care. 2009 Sep;32(9):1721-6.
49. Yamagata H, Kiyohara Y, Nakamura S, et al. Impact of fasting plasma glucose levels on gastric cancer incidence in a general Japanese population: the Hisayama study. Diabetes Care. 2005 Apr;28(4):789-94.
50. Pereg D, Elis A, Neuman Y, Mosseri M, Lishner M, Hermoni D. Cardiovascular risk in patients with fasting blood glucose levels within normal range. Am J Cardiol. 2010 Dec 1;106(11):1602-5.
51. Srinivasan M, Sudheer AR, Menon VP. Ferulic acid: therapeutic potential through its antioxidant property. J Clin Biochem Nutr. 2007 March;40(2):92-100.
52. Glei M, Kirmse A, Habermann N, Persin C, Pool-Zobel, BL. Bread enriched with green coffee extract has chemoprotective and antigenotoxic activities in human cells. Nutr Cancer. 2006;56(2):182-92.
53. Suzuki A, Yamamoto N, Jokura H, et al. Chlorogenic acid attenuates hypertension and improves endothelial function in spontaneously hypertensive rats. J Hypertens. 2006 Jun;24(6): 1065-73.
54. Watanabe T, Arai Y, Mitsui Y, et al. The blood pressure-lowering effect and safety of chlorogenic acid from green coffee bean extract in essential hypertension. Clin Exp Hypertens. 2006;28:439-49.
55. Ochiai R, Jokura H, Suzuki A, et al. Green coffee bean extract improves human vasoreactivity. Hypertens Res. 2004 Oct;27(10):731-7.
56. Onakpoya I, Terry R, Ernst E. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract. 2011;2011.
57. Salazar-Martinez E, Willett WC, Ascherio A, et al. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med. 2004 Jan 6;140(1):1-8.
58. Pereira MA, Parker ED, Folsom AR. Coffee consumption and risk of type 2 diabetes mellitus: an 11-year prospective study of 28 812 postmenopausal women. Arch Intern Med. 2006 Jun 26;166(12):1311-6.
59. Johnston KL, Clifford MN, Morgan LM. Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Am J Clin Nutr. 2003 Oct;78(4):728-33.
60. Bidel S, Hu G, Sundvall J, Kaprio J, Tuomilehto J. Effects of coffee consumption on glucose tolerance, serum glucose and insulin levels--a cross-sectional analysis. Horm Metab Res. 2006 Jan;38(1):38-43.
61. van Dam RM, Feskens EJM. Coffee consumption and risk of type 2 diabetes mellitus. Lancet. 2002 Nov 9;360(9344):1477-8.
62. Available at: http://www.illy.com/wps/wcm/connect/us/illy/the-world-of-coffee/the-science-of-coffee/. Accessed July 6, 2011.
63. McCarty MF. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med Hypotheses. 2005;64(4):848-53.
64. Greenberg JA, Boozer CN, Geliebter A. Coffee, diabetes, and weight control. Am J Clin Nutr. 2006 Oct;84(4):682-93.
65. Henry-Vitrac C, Ibarra A, Roller M, Merillon JM, Vitrac X. Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. J Agric Food Chem. 2010 Apr 14;58(7):4141-4.
66. Andrade-Cetto A, Vazquez RC. Gluconeogenesis inhibition and phytochemical composition of two Cecropia species. J Ethnopharmacol. 2010 Jul 6;130(1):93-7.
67. Bassoli BK, Cassolla P, Borba-Murad GR, et al. Chlorogenic acid reduces the plasma glucose peak in the oral glucose tolerance test: effects on hepatic glucose release and glycaemia. Cell Biochem Funct. 2008 Apr;26(3):320-8.
68. Ishikawa A, Yamashita H, Hiemori M, et al. Characterization of inhibitors of postprandial hyperglycemia from the leaves of Nerium indicum. J Nutr Sci Vitaminol (Tokyo). 2007 Apr;53(2):166-73.
69. Herrera-Arellano A, Aguilar-Santamaria L, Garcia-Hernandez B, Nicasio-Torres P, Tortoriello J. Clinical trial of Cecropia obtusifolia and Marrubium vulgare leaf extracts on blood glucose and serum lipids in type 2 diabetics. Phytomedicine. 2004 Nov;11(7-8):561-6.
70. Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J Int Med Res. 2007 Nov-Dec;35(6):900-8.
71. van Dijk AE, Olthof MR, Meeuse JC, Seebus E, Heine RJ, van Dam RM. Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care. 2009 Jun;32(6):1023-5.
72. Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC Complement Altern Med. 2006;6:9.
73. Cho AS, Jeon SM, Kim MJ, et al. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010 Mar;48(3):937-43.
74. Li SY, Chang CQ, Ma FY, Yu CL. Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-alpha in golden hamsters fed on high fat diet. Biomed Environ Sci. 2009 Apr;22(2):122-9.
75. Murase T, Misawa K, Minegishi Y, Aoki M, Ominami H, Suzuki Y, Shibuya Y, Hase T. Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice. Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E122-33.
76. Zhang LT, Chang CQ, Liu Y, Chen ZM. Effect of chlorogenic acid on disordered glucose and lipid metabolism in db/db mice and its mechanism. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Jun;33(3):281-6.
77. Donahue RP, Abbott RD, Reed DM, et al: Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes. 1987 Jun;36 (6):689-92.
78. Hemmerle H, Burger HJ, Below P, et al. Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. J Med Chem. 1997 Jan 17;40(2):137-45.
79. Kaleta C, de Figueiredo LF, Werner S, Guthke R, Ristow M, Schuster S. In silico evidence for gluconeogenesis from Fatty acids in humans. PLoS Comput Biol. 2011 Jul;7(7):e1002116.
80. Titov VN, Dmitriev LF, Krylin VA. [Methylglyoxal--test for biological dysfunctions of homeostasis and endoecology, low cytosolic glucose level, and gluconeogenesis from fatty acids]. Ter Arkh. 2010;82(10):71-7.
81. DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl. 2004 Oct (143):9-21.
82. Tonelli J, Kishore P, Lee DE, Hawkins M. The regulation of glucose effectiveness: how glucose modulates its own production. Curr Opin Clin Nutr Metab Care. 2005 Jul;8(4):450-6.
83. Mlinar B, Marc J, Janez A, Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta. 2007 Jan;375(1-2):20-35.
84. Goldstein JL, Zhao TJ, Li RL, Sherbet DP, Liang G, Brown MS. Surviving Starvation: Essential Role of the Ghrelin-Growth Hormone Axis. Cold Spring Harb Symp Quant Biol. 2011 Jul 22.
85. Finn PF, Dice JF. Proteolytic and lipolytic responses to starvation. Nutrition. 2006 Jul-Aug;22(7-8):830-44.
86. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2•7 million participants. Lancet. 2011 Jul 2;378(9785):31-40
87. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9•1 million participants. Lancet. 2011 Feb 12;377(9765):557-67.
88. Cosson E, Hamo-Tchatchouang E, Banu I, et al. A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients. Diabetes Metab. 2010 Sep;36(4):312-8.